Secins – Cytohesin Inhibitors
Compounds for the inhibition of EGFR-signalling.
Invention: Pharmacological inhibition of cell proliferation, adhesion and migration is pivotal in the treatment of a wide variety of cancers. A prominent protein involved in these processes and associated with the onset of cancer in humans is the EGF receptor. It was surprisingly found by the inventors that cytohesins are a pathophysiologically relevant class of cytoplasmatic EGFR activators. Therefore, they are an attractive target for the modulation of different disease-relevant signal transduction pathways. A correlation of cytohesin expression with EGFR-signalling could already be shown for human lung adenocarcinoma. By cytohesin inhibition, therapeutic interventions may be possible in the future. The present invention discloses small molecules which combine a highly selective inhibitory effect on cytohesins with cell permeability and low toxicity.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…